1. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
- Author
-
McNicholl JM, Bond KB, Ruhadze ER, Olsen MR, Takayama K, and Hunter RL
- Subjects
- Amino Acid Sequence, Animals, Cross Reactions, Cytoskeletal Proteins immunology, Drug Combinations, Female, Humans, Immunoglobulin G immunology, Immunoglobulin Isotypes, Kinetics, Lipid A analogs & derivatives, Lipid A immunology, Lipopolysaccharides immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Peptides immunology, Polymers, Time Factors, AIDS Vaccines immunology, Adjuvants, Immunologic, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology, HIV-1 immunology, Peptide Fragments immunology, Poloxalene, Vaccines, Synthetic immunology
- Abstract
Improvements in HIV-1 vaccines are urgently needed since many of the available vaccines are weak immunogens. We examined the ability of CRL1005, a novel nonionic block copolymer adjuvant, to improve the immunogenicity of multiple HIV-1 envelope vaccines: six gp120s and single and multiple V3 peptides (MAPs). Formulation of vaccine with adjuvant, as compared with alum or saline, enhanced antibody titer in mice up to 200-fold, with antibody half-lives of >200 days. For most vaccinations, an oil-in-water formulation induced the highest antibody titers; for some antigens, however, particularly single peptides, water-in-oil (w/o) was better. Antigen cross-reactivity was optimized by formulation in w/o, while addition of detoxified lipopolysaccharide enhanced levels of IgG2a and IgG2b. After more than 1 year of observation, no vaccine-related toxicity was observed and emulsified antigen in encapsulated depots was found at immunization sites of w/o-immunized animals. No other adjuvant has been reported to induce such long-lasting antibodies, and the ability of CRL1005 to greatly amplify and qualitatively modify antibody responses suggests that it may be useful in developing improved HIV vaccines for humans.
- Published
- 1998
- Full Text
- View/download PDF